This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
OKYO Pharma Bilan de santé
Santé financière contrôle des critères 2/6
OKYO Pharma has a total shareholder equity of £-2.1M and total debt of £2.2M, which brings its debt-to-equity ratio to -107.9%. Its total assets and total liabilities are £5.2M and £7.3M respectively.
Informations clés
-107.9%
Ratio d'endettement
UK£2.22m
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | UK£4.05m |
Fonds propres | -UK£2.05m |
Total du passif | UK£7.26m |
Total des actifs | UK£5.20m |
Mises à jour récentes de la santé financière
Recent updates
Analyse de la situation financière
Passif à court terme: OK10 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: OK10 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: OK10 has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: OK10's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: OK10 has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Prévisions de trésorerie: OK10 is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.